Unknown

Dataset Information

0

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies.


ABSTRACT:

Background

Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors therapy is now a routine scheme in cancers. However, the effect of preexisting autoantibodies on the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients is not well understood.

Methods

The present retrospective cohort study evaluated the safety and efficacy of PD-1/PD-L1 inhibitors in patients with preexisting autoantibodies. Patients who received PD-1/PD-L1 inhibitors in the Department of Medical Oncology, Peking Union Medical College Hospital between November 2017 and August 2021 were reviewed.

Results

67 (37.9%) of the 177 patients, 27 (20.3%) of the 133 patients, and 16 (11.0%) of 146 patients who received PD-1/PD-L1 inhibitors were positive for ANA, anti-Ro52, and antithyroid antibodies, respectively. Preexisting ANA and anti-Ro52 antibody were not associated with the increased risk of immune-related adverse events (irAEs), while thyroid dysfunction was more frequent in patients with positive antithyroid antibody (75.0% versus 13.8%, p < 0.001). The median progression-free survival (PFS, 13.1 versus 7.0 months, p = 0.015) was significantly longer in the ANA-positive patients, while the median overall survival (OS, 14.5 versus 21.8 months, p = 0.67) did not differ significantly between the ANA-positive and ANA-negative groups. Moreover, the preexisting anti-Ro52 and antithyroid antibodies were not significantly associated with PFS and OS.

Conclusions

The presence of ANA and anti-Ro52 antibody were not associated with a higher risk of irAEs, whereas patients positive for antithyroid antibody should monitor closely immune-related thyroid dysfunction. Preexisting ANA might be a predictor of longer PFS, while anti-Ro52 and antithyroid antibodies had no significant effect on survival outcomes in patients receiving PD-1/PD-L1 inhibitors therapy.

SUBMITTER: Tang H 

PROVIDER: S-EPMC9148956 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies.

Tang Hui H   Geng Ruixuan R   Xu Xiuxiu X   Wang Yingyi Y   Zhou Jiaxin J   Zhang Shulan S   Zhao Lin L   Guan Mei M   Bai Chunmei C  

Frontiers in immunology 20220516


<h4>Background</h4>Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors therapy is now a routine scheme in cancers. However, the effect of preexisting autoantibodies on the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients is not well understood.<h4>Methods</h4>The present retrospective cohort study evaluated the safety and efficacy of PD-1/PD-L1 inhibitors in patients with preexisting autoantibodies. Patients who received PD-1/PD-L1 inhibitors in  ...[more]

Similar Datasets

| S-EPMC8971753 | biostudies-literature
| S-EPMC5836064 | biostudies-other
| S-EPMC6129950 | biostudies-literature
| S-EPMC7873939 | biostudies-literature
| S-EPMC9097585 | biostudies-literature
| S-EPMC6779807 | biostudies-literature
| S-EPMC7937882 | biostudies-literature
| S-EPMC10803485 | biostudies-literature
| S-EPMC9889821 | biostudies-literature
| S-EPMC9913120 | biostudies-literature